Hypertension Research

Hypertension Research is the official journal of the Japanese Society of Hypertension, published by Springer Nature and covering all aspects of hypertension and related cardiovascular disease, with a 2025 Journal Impact Factor of 5.0.《高血压研究》（Hypertension Research）是日本高血压学会的会刊，由（Springer Nature）出版，覆盖高血压及相关心血管疾病的各个方面，2025 年期刊影响因子为 5.0。

Scope

• The journal publishes high-quality original research articles, reviews, correspondence and editorials on hypertension and related cardiovascular diseases.刊物发表关于高血压及相关心血管疾病的高质量原创论文、综述、通信与社论。
• It welcomes clinical trials, clinical and epidemiological studies, and basic research.刊物欢迎临床试验、临床与流行病学研究以及基础研究。
• Basic science coverage includes pathophysiology, genetics, metabolomics, pharmacology, molecular biology and biomarkers.基础科学方面覆盖病理生理学、遗传学、代谢组学、药理学、分子生物学与生物标志物。
• The scope has been expanded to include organ damage, vascular dysfunction and cerebrovascular disease.刊物范围已扩展至靶器官损害、血管功能障碍与脑血管疾病。
• Chronic kidney disease and metabolic disease are also within the journal's declared interests.慢性肾脏病与代谢性疾病也属刊物公开的关注范围。
• The journal emphasises research that can be translated into better control of blood pressure and improved cardiovascular outcomes.刊物强调可转化为更好的血压控制与心血管结局改善的研究。

History

• The journal traces its history to the journal of the Japanese Society of Hypertension, founded in 1978.刊物可追溯至 1978 年创办的日本高血压学会会刊。
• From volume 15 in 1992 it has been published under the title Hypertension Research, with the subtitle Clinical and Experimental used until volume 22.自 1992 年第 15 卷起，刊物以《高血压研究》为刊名出版，副题「临床与实验」沿用至第 22 卷。
• The journal has a history of more than four decades and marked its 45th year around 2023.刊物已有四十余年历史，并在 2023 年前后迎来创刊 45 年。
• It has been published on behalf of the Japanese Society of Hypertension by Springer Nature, and appears on the Nature portfolio platform.刊物由（Springer Nature）代表日本高血压学会出版，并发布于自然系列平台。
• From January 2019 the journal moved to online-only publication and ceased printing issues for subscribers.自 2019 年 1 月起，刊物转为仅在线出版，不再向订户提供纸质版。
• Submissions exceeded 800 manuscripts in 2022, and the editorial board was renewed in 2023 with an explicit goal of globalisation.2022 年投稿量超过 800 篇，2023 年刊物改组编委会，明确提出国际化目标。
• Its 2025 Journal Impact Factor is 5.0, after 4.6 in 2024, 5.528 in 2022 and 3.872 in 2021, and it ranks in the first quartile of peripheral vascular disease.2025 年期刊影响因子为 5.0，此前 2024 年为 4.6，2022 年为 5.528，2021 年为 3.872，在外周血管病类别中位列一区。

Editors

• The Editor-in-Chief is Kazuomi Kario, a leading researcher on blood pressure variability and hypertension management in Japan.主编为（Kazuomi Kario），日本在血压变异性与高血压管理领域的领军研究者。
• Kario's work on morning hypertension and home blood pressure measurement has shaped the journal's clinical focus.（Kario）关于清晨高血压与家庭血压测量的研究塑造了刊物的临床重点。
• The journal is supported by an international editorial board and by the editorial office at the Japanese Society of Hypertension in Tokyo.刊物由国际编委会与设在东京的日本高血压学会编辑部共同支持。
• The society also supports the journal through annual prizes for the best and the two outstanding papers published in it.学会还通过年度奖项支持刊物，表彰其发表的最佳论文与两篇优秀论文。
• Manuscripts are submitted through the publisher's online system and undergo peer review, with a typical handling time of three to eight weeks.稿件经出版方在线系统提交并接受同行评审，典型处理周期为三至八周。
• The journal publishes monthly, with twelve issues a year and a hybrid open access model.刊物为月刊，每年 12 期，采用混合开放获取模式。